An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age
Phase of Trial: Phase III
Latest Information Update: 08 May 2017
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary)
- Indications Measles; Mumps; Rubella; Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors sanofi pasteur MSD
- 20 Mar 2012 Planned number of patients changed from 1260 to 1620.
- 06 Mar 2012 Results published in Vaccine.
- 08 Apr 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History